Strong growth masked by margin pressure; semaglutide setback derails targets

₹4,921 Cr reported, 54.8% YoY growth confirmed. India 19%, Brazil 27% delivered.

JB EBITDA margin 35.3%, above historical, but consolidated OPM only 33.4% vs stated 33.8%.

₹50 Cr in Q1, supply disruption July-August. Now deferring revised guidance. Target will not be met.

PAT ₹566 Cr, +3.3% YoY. Despite 55% revenue growth, profit growth stalled due to merger costs, forex headwinds.

Guided >₹100 Cr, possibly beyond. JB margin improvement and reinvestment offsetting revenue disruption.

First-year target raised from ₹90 Cr to >₹100 Cr. JB EBITDA margin 35.3% vs historical; realization ahead due to July merger early close.

Prior ₹250 Cr FY27 target abandoned after Jul-Aug supply disruption. Deferring revised guidance pending recovery trajectory; market opportunity ₹700-800 Cr YE1.

Management declined to guide FY27 margin/PAT citing integration disruptions. Will wait one more quarter for entity settlement before forward guidance.

Channel inventory correction 15-18% impact in Q1; mid-teens constant-currency growth expected Q2+. No change to long-term view.

Prior call implied FY27 revenue synergies possible. Now deferring to post-integration completion; cardiac/gastro cross-sell still viewed as opportunity.

Largely cost synergies, implemented sooner than expected. Minor operating leverage. Margins should improve sequentially as steps begun in Q4 continue.

Without correction, constant-currency sales would have grown 15-18%. Normalized mid-teens growth expected Q2+.

Still with regulator. Regulator expediting all semaglutide approvals. Timeline months, not years, but not definite.

Reps unfamiliar with territories, prescribers initially; robust transfer process but historical precedent shows transient impact. Normalization expected by Q4.

Comfortable guiding only starting next year post-integration. Cardiac, gastro, cross-sell potential remains high but won't quantify yet.

Synergy realization could be faster. Wait one or two quarters for better guidance.

Competitive launches normal. Torrent confident in double-digit share given Brazil strength in chronic/cardiac diabetes. First-mover advantage lost, a miss from our side.

Not surprising. High trial/drop-off in injectable category. Overstocking may have occurred. Expects gradual monthly improvement; oral performing well.

₹700-800 Cr market in year one, possibly larger.

Torrent 19% (per PharmaTrac): 5.1% volume, 7.7% price, ~6% new products vs market 2%, 5.8%, 3.3%. Market volume uptick higher-than-expected; wait 2-3 quarters for clarity.

Shared ₹200-250 Cr last quarter. Given Q1 ₹50 Cr trajectory pre-supply issue, would have been close to ₹250 Cr. Now supply disruption makes ₹250 impossible; deferring revised target to observe recovery.

Affected SKUs ~20% of monthly contribution. API not the issue; as long as API approved and trialed, shouldn't impact regain.

Next 6 months: focus on smooth brand transfer to Torrent divisions. After smooth execution by year-end, then growth initiatives. Can't execute both simultaneously.

US stable this year; will be profitable in US (unlike last 5 years). 17 products launched last 30 months contribute $20-25M, offsetting price erosion. Stable trajectory, won't subtract from bottom line.

Two challenges: prominent supplier (10-15% revenue) out of business. Second: cost optimization still needed to win more tenders. Still in middle of woods but making progress long-term.

Wait 12-18 months for JB comfort. India preference always; will consider mid-size international acquisitions if no India opportunities. Won't exceed 3-3.5x net debt to EBITDA.

Price increases (April annual), branded business higher contribution (76% vs 74% historically), forex positive. Sustainable up to 77%; beyond that incremental.

Guidance 0.5% annual improvement. Q1 improved 0.5% to 32.8% prior year. Expect similar trajectory.

Shared ₹200-250 Cr range last quarter. Q1 ₹50 Cr trajectory would have reached ₹250 Cr. Supply issue has derailed this.

Q1 base: 13% India, 12% intl. Integration disruptions Q2/Q3 expected but transient.

Jul-Aug supply halt derailed ₹50 Cr/quarter run rate. Alternate source secured; recovery expected end Aug.

Q1 impacted 15-18% by channel inventory correction. IQVIA +4% market; Torrent +19% with correction.

Q1 32.8% (+0.5% vs FY26). Gross margin sustainable up to 77% (prior 76.5%); EBITDA guided conservative.

Cost synergy steps started Q4, continued Q1. Further quarterly improvement expected; reinvestment offsetting some gain.

Injectable supply disruption Jul-Aug 2026 derails ₹250 Cr FY27 target. 36% market share concentrated risk. Alternate source secured but recovery timeline uncertain. 20% of monthly sales (~₹10 Cr/mo) at risk Jul-Aug.

Brand transfer from JB to Torrent divisions in Q2/Q3 will cause transient revenue impact as reps learn new territories/prescribers. Cardiac explicitly mentioned. Management expects normalization by Q4 but history shows integration surprises.

Prominent supplier representing 10-15% of Germany revenues (est. €3-4M of €29M) out of business. Market share eroding (7% to 5% in 5 years). Cost structure still uncompetitive in tender process despite optimization efforts. No clear exit timeframe.

ANVISA filing still pending; 5+ competitors already approved. Brazil is second-largest branded market after India. Lost first-mover advantage; double-digit market share capture now uncertain. Timeline 'months, not years' per management guess, not definite commitment.

PAT ₹566 Cr +3.3% YoY despite ₹4,921 Cr revenue +54.8% signals structural margin compression, not temporary. JB integration costs, forex headwinds, and semaglutide supply losses absorbed all synergy gains. NPM 11.5% is weak; OPM 33.4% flat YoY.

India IPM volume growth unexpectedly high (2% market vs historical <1-2%). Torrent 5.1% volume growth. One-quarter phenomenon; drivers unknown (trade generics shift? population uptake?). Analyst consensus uncertain if sustainable.